SCHEMBL3017633

SCHEMBL3017633

O=S(=O)(c1ccc(Cl)c(Cl)c1)N1CCN(c2nc(Cc3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HSD11B1 P28845 3/20 0.46
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
THRB P10828 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
LPAR1 Q92633 3/20 0.40
LPAR2 Q9HBW0 3/20 0.40
LMNA P02545 2/20 0.40
RAB9A P51151 1/20 0.40
MAPK1 P28482 2/20 0.39
PKM P14618 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013972 0.95 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL3018425 0.93 ALDH1A1 (0.49) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL3000583 0.91 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1ALDH1A1MAPTUSP2
SCHEMBL3655130 0.90 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL3003675 0.90 L3MBTL1 (0.44) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL3021973 0.90 THRB (0.47) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL3010593 0.90 ALDH1A1 (0.62) SMN1; SMN2L3MBTL1ALDH1A1MAPTUSP2
SCHEMBL3008545 0.89 ALDH1A1 (0.48) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL3002305 0.89 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1ALDH1A1HSD11B1MAPT
SCHEMBL2998933 0.89 VCAM1 (0.49) SMN1; SMN2L3MBTL1ALDH1A1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.